These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 11757723)

  • 41. [Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
    Ribera JM; Grañena A; Rozman C; Urbano-Ispizua A; Bladé J; Carreras E; Cervantes F; Marín P; Sierra J; Nomdedeu B
    Sangre (Barc); 1990 Feb; 35(1):26-32. PubMed ID: 2333581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma.
    Patte C; Kalifa C; Flamant F; Hartmann O; Brugières L; Valteau-Couanet D; Bayle C; Caillaud JM; Lemerle J
    Med Pediatr Oncol; 1992; 20(2):105-13. PubMed ID: 1734214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
    Cavalieri E; Matturro A; Annechini G; De Angelis F; Frattarelli N; Gentilini F; Grapulin L; Sacco M; Torelli F; Vignetti M; Mandelli F; Foà R; Pulsoni A
    Leuk Lymphoma; 2009 Nov; 50(11):1803-8. PubMed ID: 19860621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients.
    Kaiser U; Uebelacker I; Havemann K
    Leuk Lymphoma; 1999 Dec; 36(1-2):101-8. PubMed ID: 10613454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
    Mottl H; Bajciova V; Nemec J; Al Shemmari S; Al Awadi S
    Pediatr Hematol Oncol; 2003 Mar; 20(2):103-10. PubMed ID: 12554521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
    Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology.
    Soslow RA; Baergen RN; Warnke RA
    Cancer; 1999 Jun; 85(12):2648-54. PubMed ID: 10375114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nine-year survival of lymphoblastic lymphoma patients.
    Kang W; Hahn JS; Kim JS; Cheong JW; Yang WI
    Yonsei Med J; 2006 Aug; 47(4):466-74. PubMed ID: 16941734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
    Tobinai K; Takeyama K; Arima F; Aikawa K; Kobayashi T; Hanada S; Kasai M; Ogura M; Sueoka E; Mukai K; Tajima K; Fukuda H; Shirakawa S; Hotta T; Masanori S;
    Cancer Sci; 2007 Sep; 98(9):1350-7. PubMed ID: 17640299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
    Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
    Dabaja BS; Ha CS; Thomas DA; Wilder RB; Gopal R; Cortes J; Bueso-Ramos C; Hess MA; Cox JD; Kantarjian HM
    Cancer; 2002 May; 94(10):2738-44. PubMed ID: 12173345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.
    Lester EP; Petroni GR; Barcos M; Johnson JL; Millard FE; Cooper MR; Omura GA; Frei E; Peterson BA
    Cancer Invest; 2001; 19(5):447-58. PubMed ID: 11458812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
    Kitahara H; Maruyama D; Maeshima AM; Makita S; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Terauchi T; Kurihara H; Taniguchi H; Komatsu N; Tobinai K
    Ann Hematol; 2017 Mar; 96(3):411-420. PubMed ID: 27928587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
    Hong CR; Kang HJ; Park KD; Shin HY; Ahn HS
    Int J Hematol; 2018 Mar; 107(3):355-362. PubMed ID: 29052026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.
    Park SR; Kim JH; Kim DY; Lee S; Lee SY; Choi IS; Yoon SS; Park S; Kim BG; Kim NK
    Korean J Intern Med; 2003 Mar; 18(1):21-8. PubMed ID: 12760264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.